Published in
Elsevier, Annals of Oncology, 2(31), p. 228-235, 2020
DOI: 10.1016/j.annonc.2019.10.018
Links
Tools
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
Journal article published in 2020 by
M. Moehler 
,
A. Maderer,
P. C. Thuss-Patience,
B. Brenner,
J. Meiler,
T. J. Ettrich,
R.-D. Hofheinz,
S. E. Al-Batran,
A. Vogel,
L. Mueller,
M. P. Lutz,
F. Lordick,
M. Alsina,
K. Borchert,
R. Greil
and other authors.
,
A. Maderer,
P. C. Thuss-Patience,
B. Brenner,
J. Meiler,
T. J. Ettrich,
R.-D. Hofheinz,
S. E. Al-Batran,
A. Vogel,
L. Mueller,
M. P. Lutz,
F. Lordick,
M. Alsina,
K. Borchert,
R. Greil
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 